{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:37:06Z","timestamp":1757619426713,"version":"3.44.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Prostate cancer (PCa) is the second most common cause of cancer related deaths in men in the UK. A national screening programme for PCa does not exist due to the unsuitability of the total prostate specific antigen (tPSA) test which is not specific for PCa and has a high false positive rate. Serum tPSA was measured in <jats:italic>n<\/jats:italic>\u2009=\u200925,356 male Randox Health clients. A biomarker-based (tPSA, EGF, MCP-1, IL-8) prostate cancer risk score (PCRS) was then applied to a retrospective cohort (<jats:italic>n<\/jats:italic>\u2009=\u20091,142\/25,356) of individuals to assess PCa risk. A comparative analysis between tPSA and PCRS indicated that 90.5% of the cohort were assigned low risk of PCa. Of those with an elevated PCRS, 67.8% (78\/115) had a normal tPSA value based on tPSA age-adjusted cut-offs. In addition, we observed a significant negative correlation between increasing body mass index (BMI) in men with high BMI (\u2265\u200930) and tPSA levels. No correlation was observed between BMI and PCRS. The tPSA test is potentially unsuitable for use in males with BMI\u2009\u2265\u200930. Use of PCRS could provide more accurate PCa risk stratification for males with BMI\u2009\u2265\u200930. Future assessment of the clinical utility of PCRS is warranted.<\/jats:p>","DOI":"10.1038\/s41598-025-13036-w","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:28:19Z","timestamp":1753313299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of a BMI-independent biomarker-based prostate cancer risk score to identify and triage individuals at risk of prostate disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Joanne","family":"Watt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allister","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jo","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardev","family":"Pandha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lamont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le Roy","family":"Dowey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0988-2436","authenticated-orcid":false,"given":"Mark W.","family":"Ruddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"13036_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James, N. D. et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 403, 1683-1722.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2 (2024).","journal-title":"Lancet"},{"key":"13036_CR2","unstructured":"Cancer Research UK. Prostate Cancer Statistics. Cancer Research UK https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer (2025)"},{"key":"13036_CR3","unstructured":"Ferlay, J. et al. Global Cancer Observatory: Cancer Today (version 1.1). International Agency for Research on Cancer https:\/\/gco.iarc.who.int\/today (2024)."},{"key":"13036_CR4","unstructured":"National Prostate Cancer Audit. Patient and Tumour Characteristics Associated with Metastatic Prostate Cancer at Diagnosis in England. NPCA: Short Report 2022 www.hqip.org.uk\/national-programmes (2022)."},{"key":"13036_CR5","unstructured":"Prostate Cancer UK. There\u2019s a huge North-South divide in prostate cancer diagnoses. We need your help to change it. Prostate Cancer UK https:\/\/prostatecanceruk.org\/about-us\/news-and-views\/2023\/01\/huge-north-south-divide-in-prostate-cancer-diagnoses (2023)."},{"key":"13036_CR6","unstructured":"Cancer Research UK. Survival of prostate cancer. (2022). Cancer Research UK https:\/\/www.cancerresearchuk.org\/about-cancer\/prostate-cancer\/survival (2025)."},{"key":"13036_CR7","unstructured":"Perdana, N. R., Mochtar, C. A., Umbas, R. & Hamid, A. R. A. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. Acta Med Indones 48, 228-238 (2016)."},{"key":"13036_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12916-022-02336-x","volume":"20","author":"A Perez-Cornago","year":"2022","unstructured":"Perez-Cornago, A., Dunneram, Y., Watts, E. L., Key, T. J. & Travis, R. C. Adiposity and risk of prostate cancer death: A prospective analysis in UK biobank and meta-analysis of published studies. BMC Med. 20, 143. https:\/\/doi.org\/10.1186\/s12916-022-02336-x (2022).","journal-title":"BMC Med."},{"key":"13036_CR9","unstructured":"National Institute for Health and Care Excellence. Suspected Cancer: Recognition and Referral. National Institute for Health and Care Excellence www.nice.org.uk\/guidance\/ng12 (2015)."},{"key":"13036_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/cncr.31140","volume":"124","author":"PC Albertsen","year":"2018","unstructured":"Albertsen, P. C. Prostate cancer screening with prostate-specific antigen: Where are we going?. Cancer\u00a0124, 453\u2013455; https:\/\/doi.org\/10.1002\/cncr.31140 (2018).","journal-title":"Cancer"},{"key":"13036_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.surge.2014.04.003","author":"WP Tormey","year":"2014","unstructured":"Tormey, W. P. The complexity of PSA interpretation in clinical practice. Surgeon 12, 323-327;\u00a0https:\/\/doi.org\/10.1016\/j.surge.2014.04.003 (2014).","journal-title":"Surgeon"},{"key":"13036_CR12","doi-asserted-by":"publisher","unstructured":"Ilic, D. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis. BMJ 362, k3519.\u00a0https:\/\/doi.org\/10.1136\/bmj.k3519 (2018).","DOI":"10.1136\/bmj.k3519"},{"key":"13036_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson, J. et al. A 16-yr Follow-up of the European randomized study of screening for prostate Cancer. Eur. Urol. 76, 43\u201351 (2019).","journal-title":"Eur. Urol."},{"key":"13036_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004720.pub3","author":"D Ilic","year":"2013","unstructured":"Ilic, D., Neuberger, M. M., Djulbegovic, M. & Dahm, P. Screening for prostate cancer. Cochrane Database Syst. Rev 2013, CD004720.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD004720.pub3 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10071","key":"13036_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. Lancet 389, 815-822; https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1 (2017).","journal-title":"Lancet"},{"key":"13036_CR16","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/bmjonc-2023-000057","volume":"2","author":"CM Moore","year":"2023","unstructured":"Moore, C. M. et al. Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study. BMJ Oncol. 2, e000057 (2023).","journal-title":"BMJ Oncol."},{"issue":"24","key":"13036_CR17","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.3390\/cancers15245825","volume":"15","author":"A Chatterjee","year":"2023","unstructured":"Chatterjee, A. et al. Prostate cancers invisible on multiparametric MRI: Pathologic features in correlation with whole-mount prostatectomy. Cancers 15, 5825.\u00a0https:\/\/doi.org\/10.3390\/cancers15245825 (2023).","journal-title":"Cancers (Basel)"},{"key":"13036_CR18","unstructured":"Uhr, A., Glick, L. & Gomella, L. G. An overview of biomarkers in the diagnosis and management of prostate cancer. Can. J. Urol. 27, 24-27 (2020)."},{"key":"13036_CR19","unstructured":"National Institute for Care and Excellence. Stockholm3 for Prostate Cancer Screening Medtech Innovation Briefing. National Institute for Care and Excellence www.nice.org.uk\/guidance\/mib303 (2022)."},{"key":"13036_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837127","author":"CJ McNally","year":"2022","unstructured":"McNally, C. J. et al. A novel combination of serum markers in a multivariate model to help triage patients into low- and high-risk categories for prostate cancer. Front. Oncol. 12, 837127.\u00a0https:\/\/doi.org\/10.3389\/fonc.2022.837127 (2022).","journal-title":"Front. Oncol."},{"key":"13036_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1373\/clinchem.2005.049429","volume":"51","author":"SP FitzGerald","year":"2005","unstructured":"FitzGerald, S. P., Lamont, J. V., McConnell, R. I. & Benchikh, E. O. Development of a high-throughput automated analyzer using biochip array technology. Clin. Chem.\u00a051, 1165\u20131176 (2005).","journal-title":"Clin. Chem."},{"key":"13036_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76929-y","author":"MJ Kurth","year":"2020","unstructured":"Kurth, M. J. et al. Acute kidney injury risk in orthopaedic trauma patients pre and post surgery using a biomarker algorithm and clinical risk score. Sci. Rep. 10, 20005.\u00a0https:\/\/doi.org\/10.1038\/s41598-020-76929-y (2020).","journal-title":"Sci. Rep."},{"key":"13036_CR23","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1373\/clinchem.2005.063354","volume":"52","author":"W De Ronde","year":"2006","unstructured":"De Ronde, W. et al. Calculation of bioavailable and free testosterone in men: A comparison of 5 published algorithms. Clin. Chem. 52, 1777\u20131784 (2006).","journal-title":"Clin. Chem."},{"key":"13036_CR24","unstructured":"National Institute for Health and Care Excellence. Obesity: Clinical Assessment and Management (QS127). Natioal Institute for Health and Care Excellence www.nice.org.uk\/guidance\/qs127 (2016)."},{"key":"13036_CR25","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing www.R-project.org (2024)."},{"key":"13036_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.87","author":"KJ Rothman","year":"2008","unstructured":"Rothman, K. J. BMI-related errors in the measurement of obesity. Int. J. Obes. 32, S56-S59.\u00a0https:\/\/doi.org\/10.1038\/ijo.2008.87 (2008).","journal-title":"Int. J. Obes."},{"key":"13036_CR27","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Zhang, Y., Wang, X., Lin, D. & Chen, Z. Relationship between body mass index and concentrations of prostate specific antigen: a cross-sectional study. Scand J. Clin. Lab. Invest 80, 162-167 (2020).","DOI":"10.1080\/00365513.2019.1703217"},{"key":"13036_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10552-020-01291-3","volume":"31","author":"S Harrison","year":"2020","unstructured":"Harrison, S. et al. Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes Control\u00a031, 431\u2013449. https:\/\/doi.org\/10.1007\/s10552-020-01291-3 (2020).","journal-title":"Cancer Causes Control"},{"key":"13036_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02750-2","author":"NH Phelps","year":"2024","unstructured":"Phelps, N. H. et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027-1050; https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2 (2024).","journal-title":"Lancet"},{"key":"13036_CR30","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/jnci\/djad113","volume":"115","author":"LM Hurwitz","year":"2023","unstructured":"Hurwitz, L. M., Dogbe, N., Barry, K. H., Koutros, S. & Berndt, S. I. Obesity and prostate cancer screening, incidence, and mortality in the prostate, lung, colorectal, and ovarian cancer screening trial. J. Natl. Cancer Inst.\u00a0115, 1506\u20131514 (2023).","journal-title":"J. Natl. Cancer Inst."},{"key":"13036_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.01.027","author":"JN Cornu","year":"2016","unstructured":"Cornu, J. N. et al. Impact of body mass index, age, prostate volume, and genetic polymorphisms on prostate-specific antigen levels in a control population. Eur. Urol. 70, 6-8.\u00a0https:\/\/doi.org\/10.1016\/j.eururo.2016.01.027 (2016).","journal-title":"Eur. Urol."},{"key":"13036_CR32","first-page":"1465","volume":"27","author":"S Harrison","year":"2016","unstructured":"Harrison, S. et al. Investigating the prostate specific antigen, body mass index and age relationship: Is an age\u2013BMI-adjusted PSA model clinically useful?. Cancer Causes Control\u00a027, 1465\u20131474 (2016).","journal-title":"Cancer Causes Control"},{"key":"13036_CR33","doi-asserted-by":"publisher","unstructured":"Bosello, O., Donataccio, M. P. & Cuzzolaro, M. Obesity or obesities? Controversies on the association between body mass index and premature mortality. Eat Weight Disord. 21, 165-174. https:\/\/doi.org\/10.1007\/s40519-016-0278-4 (2016).","DOI":"10.1007\/s40519-016-0278-4"},{"key":"13036_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","volume":"16","author":"R Ross","year":"2020","unstructured":"Ross, R. et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity. Nat. Rev. Endocrinol. 16, 177\u2013189 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"13036_CR35","unstructured":"British Heart Foundation. Why your Waist Size Matters. British Heart Foundation https:\/\/www.bhf.org.uk\/informationsupport\/heart-matters-magazine\/medical\/measuring-your-waist#:~:text=A%20larger%20waist%20may%20also,disease%20and%20type%202%20diabetes (2024)."},{"key":"13036_CR36","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1530\/ERC-17-0438","volume":"25","author":"AT Aref","year":"2018","unstructured":"Aref, A. T. et al. The inverse relationship between prostate specific antigen (PSA) and obesity. Endocr. Relat. Cancer. 25, 933\u2013941 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"13036_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prnil.2015.08.001","volume":"4","author":"D Parikesit","year":"2016","unstructured":"Parikesit, D., Mochtar, C. A., Umbas, R. & Hamid, A. R. A. H. The impact of obesity towards prostate diseases. Prostate Int.\u00a04, 1\u20136. https:\/\/doi.org\/10.1016\/j.prnil.2015.08.001 (2016).","journal-title":"Prostate Int."},{"key":"13036_CR38","doi-asserted-by":"crossref","unstructured":"Sachdev, S., Cucchiara, A. J. & Snyder, P. J. Prostate-specific antigen concentrations in response to testosterone treatment of severely hypogonadal men. J Endocr Soc. 4, bvaa141 (2020).","DOI":"10.1210\/jendso\/bvaa141"},{"key":"13036_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jsxm.2022.01.003","volume":"19","author":"JM Flores","year":"2022","unstructured":"Flores, J. M. et al. The relationship between PSA and total testosterone levels in men with prostate cancer. J. Sex. Med.\u00a019, 471\u2013478 (2022).","journal-title":"J. Sex. Med."},{"key":"13036_CR40","unstructured":"Prostate Cancer UK.  Introducing TRANSFORM, our \u00a342 million trial to find a screening programme for prostate cancer. Prostate Cancer UK  www.prostatecanceruk.org\/about-us\/news-and-views\/2023\/11\/introducing-transform (2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13036-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:00:26Z","timestamp":1757278826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13036-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13036"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13036-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MR, AI, JW, MJK, LM, and JL are employees of Randox Laboratories Ltd., but hold no shares in the company. GS and MR are employees of Randox Health GB but hold no shares in the company. PF is the Managing Director and owner of Randox Laboratories Ltd., and Randox Health GB. HP and LD have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and\/or discussion reported in this paper. A patent application has been filed to protect the biomarker combination disclosed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Consent was recorded digitally through the Randox portal, and all individual data were anonymised. The study was reviewed and approved by Ulster University School of Biomedical Sciences Ethic Filter Committee (Project Number: FCBMS-24-187).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"26864"}}